XBiotech Inc.
XBIT Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.85
KIRA · Stoqly’s AI analyst, in plain words
- XBiotech Inc. lost $45.5M in fiscal 2025.
- Free cash flow was −$40.2M in fiscal 2025, — of revenue.
Market cap
$56.4M
P/E
—
Revenue
—
Net income
−$45.5M
Free cash flow
−$40.2M
Operating margin
—
XBiotech Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$45.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What XBiotech Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- XBiotech Inc.
- CIK
- 0001626878
XBiotech Inc. · XBIT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $18.4M | $4.0M | $0.0M | — | — |
| Revenue growth | −58.2% | −78.2% | −100.0% | — | — |
| Gross margin | 68.4% | 83.8% | — | — | — |
| Operating margin | −136.4% | −860.1% | — | — | — |
| Net income | −$17.4M | −$32.9M | −$24.6M | −$38.5M | −$45.5M |
| Net margin | −94.7% | −820.4% | — | — | — |
| Diluted EPS | −$0.58 | −$1.08 | −$0.81 | −$1.26 | −$1.49 |
| Cash | |||||
| Cash from operations | $69.4M | −$14.8M | −$18.7M | −$31.0M | −$39.9M |
| Capital expenditure | $3.5M | $0.6M | $0.4M | $1.3M | $0.3M |
| Free cash flow | $65.9M | −$15.4M | −$19.1M | −$32.3M | −$40.2M |
| FCF margin | 358.4% | −384.3% | — | — | — |
| Dividends paid | $75.0M | $0.0M | — | — | — |
| Share buybacks | — | $0.0M | $0.0M | $0.0M | — |
| Share count change | −2.5% | 1.3% | −0.0% | 0.1% | 0.1% |
| Debt and strength | |||||
| Cash and short-term investments | $237M | $217M | $200M | $173M | $126M |
| Shareholders' equity | $269M | $240M | $219M | $182M | $140M |
| Current ratio | 71.5x | 54.1x | 33.1x | 11.6x | 16.0x |
| Returns and quality | |||||
| Return on equity | −5.6% | −12.9% | −10.7% | −19.2% | −28.2% |
| Return on tangible equity | −6.5% | −13.7% | −11.2% | −21.1% | −32.4% |
| Piotroski F-score | 4 | 2 | 3 | — | — |
| Altman Z'' | 54.1 | 48.7 | 33.4 | 13.7 | 14.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
XBiotech Inc. · XBIT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.85 a share, the company is worth $56.4M.
Source: SEC EDGAR XBRL filings (CIK 0001626878). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.